Eli Lilly is spending some of its GLP-1 money to buy up CAR-T gene therapy researchers. UBS analyst Michael Yee thinks that's smart strategy. So what does this Wall Street analyst like about Lilly?

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy pretty vague. This time, Lilly has returned to antibody-drug conjugates (ADCs), ...

Eli Lilly LLY.N said on Thursday its newly approved obesity pill was not inferior to a widely used long-acting insulin at lowering the risk of major heart problems in patients with type 2 diabetes and ...

The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, including whether it could be linked to liver and heart problems, according to ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Wall Street impressed with initial prescriptions for Lilly's Foundayo Lilly cautions early weekly figures may not be fully comprehensive Demand for Novo Nordisk's oral Wegovy also strong April 17 ...

Eli Lilly’s LLY3.07%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new data in diabetes Thursday that also serve to address the FDA’s desire for ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the company's underlying valuation metrics are quite modest. Eli Lilly stock might ...

Eli Lilly's LLY.N newly launched weight-loss pill was prescribed 1,390 times in the U.S. in its first week of sales, according to analysts who cited IQVIA data, indicating that its push into oral ...